Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- PRCT.NASDAQ
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
PROCEPT BioRobotics (PRCT) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
STRONG BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY$25
+27.1%5-Year
STRONG BUY$57
+192.9%Published batch insight
Hidden Surgical Consumable Annuity Set to Overcome Hospital Channel Inventory Reset
There is high consensus that clinical demand remains robust beneath transient channel destocking, driven by recurring waterjet consumable utilization and gross margins reaching 66%. However, sharp divergence persists regarding the five-year cash-burn runway, debt refinancing risks, and regulatory oncology timing.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Sherlock Holmes (Whistleblower), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Elon Musk (Visionary), Universal Investor (Polymath), J.P. Morgan (Titan), Ray Dalio (Strategist), Michael Burry (Vulture), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTFull published thesis
Executive Summary
If you invested $10,000 in PROCEPT BioRobotics at the forecast anchor (2026-09-18): $29,290 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 19.60 | +1.57% | +1.57% | Third-quarter results confirm hospital handpiece destocking has largely concluded, with shipments tracking actual procedure volumes. Macro headwinds from elevated interest rates and ongoing securities litigation cap immediate multiple expansion, resulting in modest stabilization. |
| Q1 2027 | 20.66 | +5.38% | +7.04% | Full-year 2026 financial reporting proves underlying procedure growth exceeded 20%, while conservative 2027 guidance resets Street expectations. Clean handpiece utilization data prompts short covering and stabilizes the valuation floor above distress levels. |
| Q2 2027 | 23.21 | +12.36% | +20.27% | Presentation of primary endpoint results from the WATER IV trial at the urology congress generates clinical excitement regarding functional preservation. Expanding HYDROS console installations and high-margin consumable reorders drive solid quarterly appreciation. |
| Q3 2027 | 24.53 | +5.67% | +27.08% | Focus shifts to balance-sheet duration as the October 2027 debt amortization window approaches. Continued procedural expansion offsets refinancing friction, though higher interest rates maintain valuation multiple pressure across mid-cap medical technology. |
| Q4 2027 | 26.47 | +7.93% | +37.16% | Management successfully renegotiates or terms out credit facilities, eliminating near-term liquidity panic. Year-end surgical procedure backlogs clear, driving handpiece reorders higher and narrowing quarterly operating cash burn. |
| Q1 2028 | 28.42 | +7.38% | +47.28% | Full-year 2027 earnings demonstrate gross margins stabilizing near 66% as research spending post-WATER IV enrollment moderates. Visible progress toward adjusted EBITDA breakeven encourages fundamental institutional healthcare allocators to accumulate shares. |
| Q2 2028 | 30.41 | +7.00% | +57.59% | Supplemental regulatory filings for oncology label expansion advance, while international placements in Western Europe and Japan accelerate. Expanding procedural volume cushions against seasonal surgical moderation and capital procurement scrutiny. |
| Q3 2028 | 31.78 | +4.49% | +64.67% | A modeled capital raise or convertible note offering dilutes per-share recovery economics slightly, causing transient price consolidation. However, recurring consumable revenue approaching 65% of sales mix provides downside support. |
| Q4 2028 | 34.47 | +8.45% | +78.59% | Post-financing overhang clears as third-quarter results approach operating cash-flow neutrality. Resolution or preliminary settlement of legacy securities litigation removes the primary governance discount, sparking sustained multiple expansion. |
| Q1 2029 | 36.78 | +6.70% | +90.56% | Full-year 2028 financial disclosures deliver the company's first cash-flow neutral operating print. Slower salesforce overhead growth relative to high-margin disposable handpiece revenue validates structural razor-and-blade operating leverage. |
| Q2 2029 | 39.13 | +6.39% | +102.73% | Oncology regulatory milestones and commercial pilots in ambulatory surgical centers expand procedural addressability. Commercial execution steadily dislodges legacy resections, broadening recurring revenue across high-volume regional hospital networks. |
| Q3 2029 | 40.30 | +2.99% | +108.80% | Routine summer surgical seasonality and modest multiple digestion produce mild quarterly consolidation. Underlying handpiece utilization remains resilient, preserving solid gross margin performance despite hospital procurement budgeting scrutiny. |
| Q4 2029 | 42.95 | +6.57% | +122.52% | Fourth-quarter procedural acceleration delivers sustained GAAP operating profitability. Fixed manufacturing cost absorption expands gross margins toward 68%, confirming self-funded corporate sustainability to the broader market. |
| Q1 2030 | 44.57 | +3.78% | +130.93% | Full-year 2029 earnings substantiate durable double-digit revenue expansion and positive free cash flow. Healthcare index inclusions and fundamental mutual fund buying support orderly equity multiple re-rating. |
| Q2 2030 | 46.94 | +5.31% | +143.20% | International commercial distribution expands procedural penetration across Asia-Pacific markets. High surgeon retention and AI-driven FirstAssist planning workflows entrench high switching costs across the mature installed base. |
| Q3 2030 | 47.87 | +1.99% | +148.04% | Growth moderates into a mature mid-teens expansion phase as domestic market penetration deepens. Mild valuation multiple compression reflects sector rotation, but strong cash conversion prevents material price degradation. |
| Q4 2030 | 50.42 | +5.32% | +161.25% | Consecutive quarters of positive free cash generation prompt management to explore balanced capital allocation, including anti-dilutive share repurchases. Year-end elective surgery volumes drive record quarterly handpiece shipments. |
| Q1 2031 | 52.56 | +4.25% | +172.35% | Fiscal 2030 results demonstrate robust return on invested capital and operating margins topping 14%. The company completes its transition from speculative turnaround to established medical technology cash compounder. |
| Q2 2031 | 54.67 | +4.01% | +183.27% | Next-generation platform software upgrades sustain console replacement cycles across pioneer hospital accounts. High-margin consumable revenue commands an enduring quality premium, insulating earnings from broader macroeconomic volatility. |
| Q3 2031 | 56.53 | +3.40% | +192.90% | Five-year forecast horizon concludes with Aquablation firmly institutionalized as standard of care. Sustainable organic free cash flow, pristine balance sheet health, and recurring razor-and-blade economics anchor long-term terminal value. |
The base-case investment thesis identifies an asymmetric valuation dislocation where forensic channel inventory digestion masked durable clinical adoption. While reported revenue growth decelerated from historical hypergrowth due to the cessation of aggressive distributor bulk discounting, underlying U.S. procedure volumes expanded 21% year-over-year in mid-2026, with handpiece shipments re-anchoring to procedure volume at 98% parity. As the global installed base of over 1,036 robotic systems matures, high-margin single-use handpieces generate an expanding recurring revenue annuity at 66% gross margins. Operating leverage will systematically absorb fixed commercial overhead as WATER IV trial enrollment costs roll off, driving the business toward adjusted EBITDA breakeven by late 2027 and free cash flow self-sufficiency by 2029. Valuation sensitivity centers on the bridge between cash burn and refinancing timing: trailing twelve-month free cash outflows of $85 million to $126 million against approximately $228 million in liquid reserves leave roughly five quarters of standalone runway. The primary counterargument warns that hospital capital expenditure rationing under restrictive monetary policy, paired with pending securities class-action liabilities, could force a dilutive equity raise before operational self-sufficiency is achieved.
Key insights
- Consumable handpiece sales expanding to over 65% of total revenue structurally decouples financial growth from lumpy hospital capital expenditure cycles.
- Restructured executive incentives under Larry Wood eliminate volatile end-quarter discounting, establishing transparent revenue quality that commands institutional multiple expansion.
- Oncology label expansion via WATER IV represents an unpriced call option; the base case remains fully supported by core benign urology.
This company makes advanced robotic systems that use high-speed waterjets to treat enlarged prostates without heat, protecting patients from surgical complications. The stock plunged because the former management team used aggressive discounts to push excess parts into hospital storage closets, making sales look artificially high. Now that hospitals have used up that extra inventory, real surgical demand is shining through, with actual surgeries growing over 20%. Because every surgery requires a new, high-profit disposable handpiece, each robot placed in a hospital acts like a recurring cash tollway. As surgery volumes grow and research spending winds down, the company is on track to stop losing money and become self-funding.
Key insights
- Surgeries are growing steadily, proving doctors prefer this waterjet technology over older, riskier heating techniques.
- Recurring sales of single-use surgical parts make up the majority of revenue, creating reliable ongoing cash.
- Ample cash in the bank provides enough breathing room to reach profitability without needing emergency loans.
Deep Dive
Prevailing market sentiment treats the business as a permanently impaired growth story crippled by executive channel stuffing, an 80% market capitalization collapse, and pending class-action lawsuits. Sell-side analysts anchor on top-line deceleration from 65% to 20% and trailing nine-figure cash burn, assuming elevated borrowing costs will permanently freeze hospital robotic purchases and force a distressed, highly dilutive equity recapitalization before the company achieves operational self-sufficiency.